A retrospective study assessing the frequency of defects like mutations in DNA Damage-Repair–associated genes in patients insufficiently responding to 225Ac-PSMA-617 therapy
Latest Information Update: 18 Nov 2020
At a glance
- Drugs 225 actinium PSMA (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 18 Nov 2020 New trial record